Original news and analysis on international IP policy
South American countries are negotiating with pharmaceutical companies to obtain common cheaper prices for high-cost medicines. The first target of initial negotiations delivered lower prices for hepatitis C and HIV. Further negotiations will be geared to additional hepatitis C, HIV and oncology medicines.
NAIROBI, Kenya -- Amid concerns over cheap imports, substandard products and counterfeits, pharmaceutical experts in East Africa are set to hold a summit early next year to discuss key challenges facing the industry in the region. Experts at the event announcement in Nairobi today stressed that technology transfer, better regulation and policy reforms can accelerate growth and spur innovation in the sector.
Last month, the World Trade Organization committee on intellectual property was suspended over two contentious items. One item left open is the proposed extension of a moratorium which leaves intellectual property outside of a mechanism through which one WTO member can go after another despite no violation of a WTO agreement. According to sources, a solution might be within reach.
This week the World Health Organization member state mechanism on falsified medicines is meeting in Geneva with a long agenda. In particular, the meeting is expected to consider a process for the mechanism review, the participation of the WHO in a global committee on the quality of health products, and several proposals including tracking systems and awareness campaigns.
Saying she could speak more freely outside of the World Health Organization, WHO Director General Margaret Chan today told a gathering of think tank representatives at the Graduate Institute of Geneva that intellectual property rights may be unfairly driving up drug prices and that industry lobbying may be interfering with governments' efforts to take action on behalf of their citizens' public health.
A recent workshop on patentability criteria illustrated how countries are using the policy space provided by international trade rules to calibrate their patent law. In particular, incremental innovation remains a trying issue for national legislators, speakers said.
The European Union Council of ministers today adopted its position on the reform of the European trademark system. The Netherlands delegation abstained from voting out of concern that the proposed reform introduces the possibility to stop goods in transit for possible intellectual property infringement.
The Medicines Patent Pool has announced the expansion of its mandate to cover hepatitis C and tuberculosis treatment. The MPP was previously concentrating only on HIV medicines.
Last week's decision by a World Trade Organization committee to allow least-developed countries to not apply global IP rules for pharmaceuticals for 17 more years made WTO members accountable to humanity, the coordinator of the LDC Group has said. Pharmaceuticals are different from all other forms of IP, he said.
After two weeks of high level negotiations between the United States and the Group of Least-Developed Countries, the World Trade Organization committee on intellectual property rights today agreed to extend a waiver allowing LDCs to avoid applying and enforcing IP rights on pharmaceutical products until 2033.
Four weeks after the finalisation of the agreement, the final text of the Trans-Pacific Partnership (TPP) was finally released by the United States and other partners of the first of the regional mega-trade deals. The parties hurried to underline the success of the negotiations, but early reactions were deeply divided.
Patent offices should align their work in support of national health and medicines policies when carrying out the examination of patents, a new South Centre paper argues.